MRD-negative status in first four heavily treated patients with "off the shelf" product ...

The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the ...

Aradigm Health, a new benefits platform aimed at easing the financial sting of coverage for cell and gene therapies, has ...

In Wiskott-Aldrich syndrome trials, therapy was associated with decreases in bleeding, inf ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...

About 100,000 people in the U.S. have sickle cell disease, a condition that primarily affects people of color, the CDC says.

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Scientists have successfully transplanted gene-edited insulin-producing cells into a man with type 1 diabetes—allowing him to ...

The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational ...

Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...